Outsourced Pharma White Papers

  1. Understanding Of Amorphous Solid Dispersions & Their Downstream Development 2/7/2022

    Understanding the properties of ASDs and their relationship to the downstream product scale up, stability, and in-vivo performance is critical to successfully utilize them for drug delivery of insoluble drugs.

  2. Extend Your Digital Edge: Bringing Production Record Data Online To Drive Intelligent Manufacturing 8/24/2021

    By definition, when data is offline or only partially digital, it’s disconnected. This white paper explores why using paper and other standalone tools as an “easy” fix to fill gaps created by disconnected systems, missing or unused software functionality, and outmoded processes presents a bigger risk and results in more missed opportunities than many manufacturers realize.

  3. What Is The True Cost Of Not Having An eQMS? 8/23/2021

    It is safe to assume that no organization that intends to stay in business sets out to manufacture or provide a low-quality product. This is particularly true for highly regulated companies. And yet switching from a manual quality management system (QMS) to an electronic one in order to improve product quality and ensure regulatory compliance remains low in most companies’ list of priorities. In this white paper we discuss the most common “quality pains” I’ve seen among regulated companies and offer some strategies on choosing and executing an eQMS.

  4. Rational Design And Development Of Long-Acting Injectable Dosage Forms 1/26/2022

    The increasing prevalence of chronic disorders, growing demand for self-administration, and the increasing demand for minimally invasive surgeries have fueled the growth of the LAI drug delivery market.

  5. Integrated First-In-Human Services To Streamline End-To-End Development And Manufacturing 6/1/2022

    Lonza’s SimpliFiH®️ Solutions offering is designed to simplify and accelerate the development pathway, even for APIs with challenging properties, such as low aqueous solubility and poor bioavailability.

  6. Expediting Early-Phase Development Of Small Molecules: An Integrated Approach 11/1/2022

    Small molecule APIs and drug products are more complex and potent than ever. Explore key strategies for efficiently advancing small molecules from API to pre-clinical data and clinical supply.

  7. Balancing Cost Efficiencies In The Drug Development Process 1/24/2022

    Cost efficiencies and expertise again go hand in hand, with companies often outsourcing or partnering primarily to gain access to manufacturing know-how.

  8. In Vitro Dissolution Methodologies For Amorphous Solid Dispersions 10/25/2021

    With the availability of so many types of in vitro dissolution tests, how do you determine which one will be most effective in predicting in vivo performance of your BCS II or IV drug product?

  9. Simultaneous Spray Drying For Combination Dry Powder Inhaler Formulations 7/12/2022

    Three combination case studies are demonstrated, in which bevacizumab is paired with erlotinib, cisplatin, or paclitaxel in a dry powder inhaler formulation.

  10. Explore Protein Function Using Surface Plasmon Resonance (SPR) 5/20/2021

    We’ve collected a few examples of how an academic research group used Biacore™ X100 SPR system in their research to investigate protein-RNA, protein-protein interactions, and how researchers have used SPR to measure antibody specificity. Download the white paper A year of interaction with Biacore™ X100.